Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
Purity: ≥98%
Erismodegib (formerly LDE-225; NVP LDE-225; LDE225; NVP-LDE22; Sonidegib; trade name of Odomzo) is an orally bioavailable small-molecule antagonist of the Smoothened (Smo) in Hedgehog signaling pathway with potential antitumor activity. It suppresses Hedgehog (Hh) signaling with an IC50 of 1.3 nM for mice and 2.5 nM for humans in cell-free assays. LDE225 (NVP-LDE225, Erismodegib, Sonidegib), an anticancer drug that has been approved, binds specifically to the cell surface receptor Smo that carries the Hedgehog (Hh) ligand. This suppresses the Hedgehog signaling pathway, which restricts the growth of tumor cells that have an aberrantly activated Hedgehog pathway. For the treatment of basal cell carcinoma, the FDA approved this anticancer medication in 2015.
Targets |
mSmo ( IC50 = 1.3 nM ); hSmo ( IC50 = 2.5 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
LLDE225 blocks the TM3 luciferized cell line with 0.6 nM and 8 nM of Hh agonist Ag1.5 present, respectively.
|
|
Cell Assay |
Prior to assessment, CD34+ CP-CML cells are cultured for 24-72 hours in SFM alone±Sonidegib±Nilotinib. BrDU incorporation colorimetric assessment is used to quantify proliferation. Utilizing annexin V-FITC and 7-amino-actinomycin D (7-AAD, Via-Probe solution), flow cytometry is used to determine the ratio of viable cells to those in early and late apoptosis. Ki67 (FITC) expression and 7-AAD incorporation are used to determine the cell cycle status.
|
|
Animal Protocol |
|
|
References |
Molecular Formula |
C26H26F3N3O3
|
---|---|
Molecular Weight |
485.5
|
Exact Mass |
485.19
|
Elemental Analysis |
C, 64.32; H, 5.40; F, 11.74; N, 8.66; O, 9.89
|
CAS # |
956697-53-3
|
Related CAS # |
Sonidegib diphosphate; 1218778-77-8
|
Appearance |
Solid powder
|
SMILES |
C[C@@H]1CN(C[C@@H](O1)C)C2=NC=C(C=C2)NC(=O)C3=CC=CC(=C3C)C4=CC=C(C=C4)OC(F)(F)F
|
InChi Key |
VZZJRYRQSPEMTK-CALCHBBNSA-N
|
InChi Code |
InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+
|
Chemical Name |
N-[6-[(2S,6R)-2,6-dimethylmorpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(trifluoromethoxy)phenyl]benzamide
|
Synonyms |
Sonidegib; LDE 225; NVP-LDE225; LDE-225; NVP LDE-225; LDE225; NVP LDE225; Erismodegib; trade name of Odomzo
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.15 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2% DMSO+corn oil: 10 mg/mL Solubility in Formulation 5: 2 mg/mL (4.12 mM) in 75% PEG 300 25% (5% dextrose in water) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0597 mL | 10.2987 mL | 20.5973 mL | |
5 mM | 0.4119 mL | 2.0597 mL | 4.1195 mL | |
10 mM | 0.2060 mL | 1.0299 mL | 2.0597 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02111187 | Completed | Drug: LDE225 | Prostate Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
April 2014 | Phase 1 |
NCT02195973 | Completed | Drug: LDE225 | Recurrent Ovarian Cancer | University of Alabama at Birmingham | September 2014 | Phase 1 |
NCT01764776 | Completed | Drug: LDE225 | Normal Hepatic Function Impaired Hepatic Function |
Novartis Pharmaceuticals | March 2013 | Phase 1 |
NCT02138929 | Completed | Drug: Everolimus Drug: LDE 225 |
Esophageal Cancer | M.D. Anderson Cancer Center | November 10, 2014 | Phase 1 |
NCT01954355 | Completed | Drug: LDE225 Drug: Paclitaxel |
Solid Tumor Ovarian Cancer |
Swiss Group for Clinical Cancer Research |
September 2013 | Phase 1 |
Antitumor activity in an orthotopic Ptch+/−p53−/−medulloblastoma allograft model in nude mice upon treatment with5mdiphosphate salt dosed at 40 mg/kg/day po bid or vehicle at equal dose volume.ACS Med Chem Lett. 2010 Jun 10; 1(3): 130–134. th> |
---|
Antitumor activity upon treatment with5mdiphosphate salt or vehicle in a Ptch+/−p53−/− medulloblastoma subcutaneous allograft model in nude mice.ACS Med Chem Lett. 2010 Jun 10; 1(3): 130–134. td> |
Gli1 mRNA inhibition (open circle), tumor PK (filled squares), and plasma PK (filled triangles) in Ptch+/−p53−/−medulloblastoma model after treatment with5m (Sonidegib, or erismodegib, LDE225, NVP-LDE225).ACS Med Chem Lett. 2010 Jun 10; 1(3): 130–134. td> |